Bevacizumab in combination with anticancer drugs for previously treated advanced non-small cell lung cancer

Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
Ke-jun LiuHai-ying Wu

Abstract

Non-small cell lung cancer (NSCLC) accounts for about 85% of all lung cancer cases. Patients with NSCLC often have an advanced disease at the time of diagnosis, with a 1-year survival rate about 10-15% under the best support treatment. As therapeutic methods for lung cancer developed rapidly in recent years, the prognosis of stage IIIB or IV NSCLC also improve to a large extend. Bevacizumab is a monoclonal antibody against VEGFR which inhibits abnormal vascular growth in malignant tumors. In October 2006, bevacizumab was approved by the U.S. Food and Drug Administration (FDA) for first-line use in advanced NSCLC. For patients with advanced NSCLC who failed in previously platinum-based chemotherapy, bevacizumab also showed enhancing efficacy to antitumor drugs recommended by the latest NCCN guideline. This review intends to present the recent progress and prospects of bevacizumab in second- or third-line treatment for patients with refractory NSCLC.

References

Jan 3, 1990·Journal of the National Cancer Institute·J Folkman
Feb 1, 1971·The Journal of Experimental Medicine·J FolkmanG Williams
May 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F A ShepherdJ Berille
Jan 11, 2002·The New England Journal of Medicine·Joan H SchillerUNKNOWN Eastern Cooperative Oncology Group
Nov 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G V ScagliottiUNKNOWN Italian Lung Cancer Project
Jun 5, 2003·Nature Reviews. Cancer·Gabriele Bergers, Laura E Benjamin
Jun 5, 2003·Nature Medicine·Napoleone FerraraJennifer LeCouter
Jul 3, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Frank FossellaChandra P Belani
Aug 21, 2003·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Petr ZatloukalMilan Kůta
Mar 3, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roy S HerbstDavid H Johnson
May 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nasser HannaPaul A Bunn
Jun 4, 2004·The New England Journal of Medicine·Herbert HurwitzFairooz Kabbinavar
Aug 18, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Román Pérez-SolerPhilip Bonomi
Nov 20, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K HottaM Tanimoto
Jul 15, 2005·The New England Journal of Medicine·Frances A ShepherdUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Jul 27, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roy S HerbstUNKNOWN TRIBUTE Investigator Group
Oct 6, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John D HainsworthAnthony Greco
Oct 21, 2005·Chest·Antonio L VisbalFrances A Shepherd
Nov 23, 2005·Oncology·Peter Carmeliet
Dec 16, 2005·Nature·Napoleone Ferrara, Robert S Kerbel
Dec 20, 2005·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Roy M BremnesRafael Sirera
Dec 15, 2006·The New England Journal of Medicine·Alan SandlerDavid H Johnson
Apr 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ulrich GatzemeierJoachim Von Pawel
Dec 19, 2007·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Fan ChenWilliam F Bina
May 29, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Giorgio Vittorio ScagliottiDavid Gandara
Oct 2, 2008·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Rebecca Suk HeistThomas J Lynch
Feb 4, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Martin ReckChristian Manegold
Apr 7, 2009·Expert Opinion on Biological Therapy·Jenia Jenab-Wolcott, Bruce J Giantonio
Apr 8, 2009·Proceedings of the American Thoracic Society·Thomas E Stinchcombe, Mark A Socinski
Oct 21, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alex A AdjeiRalph G Zinner
Feb 8, 2011·CA: a Cancer Journal for Clinicians·Ahmedin JemalDavid Forman

❮ Previous
Next ❯

Citations

Aug 29, 2016·Medical Oncology·Analia Rodríguez GarzottoM Teresa Agulló-Ortuño
Mar 30, 2017·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Ting-Qing GanGang Chen

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.